Company Description
Omnicare's pharmacy services also include distribution and patient assistance services for specialty pharmaceuticals. Omnicare offers clinical research services for the pharmaceutical and biotechnology industries in thirty countries worldwide.
Five Consecutive Surprises
On Feb 26 Omnicare released fourth-quarter and full-year results that included earnings per share of 66 cents. The number was 3 cents higher than Wall Street expected making it the fifth consecutive earnings surprise.
While full-year sales increased marginally, to $6,311 million from $6,220 million, net income grew by 37%. Income for 2008 was $156 million, up from $114 million.
Analysts are Bullish
Following the most recent earnings announcement, a vast majority of analysts have been upwardly revising their estimates. 8 of 9 covering analysts upped their forecast for 2009, which now average $2.55 per share up from $2.39 one month ago.
The 2009 consensus is calling for just over 20% earnings growth and another 10% in 2010.
Shares Trading at a Discount
A share of OCR is only going to cost an investor 8 times forward earnings and the PEG ratio is just 0.6.
The Chart
Full-year estimates are turning around. As you can see in the price and consensus chart below, forecasts had declined steadily, but are now back on the rise.
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
More Zacks Links
| Market Summary | Feb 10, 2010 09:58 am ET |

Sponsored Links 
0.28 %
-70.36
[CLICK TO CLOSE X]